NEW ORLEANS, La., and CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced positive data from a large clinical validation study of its novel prostate cancer liquid biopsy test. The study met its primary endpoint demonstrating that the urine-based liquid biopsy test when added to the current prognostic standard of care (SOC) significantly improved the ability to accurately predict high-grade prostate cancer in men presenting for an initial biopsy. James McKiernan, M.D., John K. Lattimer Professor and Chair, Department of Urology at New York-Presbyterian Hospital/Columbia University Medical Center and principal investigator of the study, presented the data today in a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.